

GenCore version 5.1.3
Copyright (c) 1993 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 16, 2003, 16:34:37, Search time 61.8429 seconds
(without alignments)
28 011 Million cell updates/sec

Title: US-09-856-070-19
Perfect score: 65
Sequence: 1 KEELMLRIQHYEE 13

Scoring table: H10SUM62
Gapop 10 0 Gapewt 0 5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database			
A_geneseq_101002.*			
1:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1989.DAT.*	2:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1990.DAT.*
3:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1991.DAT.*	4:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1992.DAT.*
5:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1993.DAT.*	6:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1994.DAT.*
7:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1995.DAT.*	8:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1996.DAT.*
9:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1997.DAT.*	10:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1998.DAT.*
11:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA1999.DAT.*	12:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2000.DAT.*
13:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2001.DAT.*	14:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2002.DAT.*
15:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2003.DAT.*	16:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2004.DAT.*
17:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2005.DAT.*	18:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2006.DAT.*
19:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2007.DAT.*	20:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2008.DAT.*
21:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2009.DAT.*	22:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2010.DAT.*
23:	/SID22/qcdata/qcdata/geneseq/geneseq-emb1/AA2011.DAT.*		

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	65	100.0	13	22	AA82037
2	65	100.0	13	22	AA82020
3	65	100.0	436	22	AA82020
4	65	100.0	586	22	AA82020
5	65	100.0	622	22	AA82020
6	65	100.0	635	22	AA82020
7	60	92.3	12	22	AA82038
8	57	87.7	52	22	AA82039
9	55	84.6	11	22	AA82039
10	41	63.1	27	20	AA82444

11	41	63.1	344	22	ABG29165	Novel human diapo
12	40	61.5	46	22	ABG42735	Peptide #10241 enc
13	40	61.5	46	22	ABG42735	Human brain exper
14	40	61.5	503	22	ABG16577	Novel human diapo
15	40	61.5	593	22	ABG19947	Novel human diapo
16	40	61.5	721	22	ABG33138	Human protein sequ
17	39	60.0	57	22	ABG39680	Peptide #7186 enco
18	39	60.0	57	22	ABG39680	Human brain exper
19	39	60.0	57	22	ABG39680	Human bone marrow
20	39	60.0	57	22	ABG39680	Peptide #7293 enco
21	39	60.0	57	22	ABG39680	Human peptide enco
22	39	60.0	405	11	ABG08119	CDX, a MILA famil
23	39	60.0	405	12	ABG13752	GDP, a MILA famil
24	39	60.0	405	13	ABG28840	HeLa cell lucosyl
25	39	60.0	405	15	AA845937	A glycosyltransfer
26	39	60.0	405	18	AA813641	Human alpha(1,3)-f
27	39	60.0	405	18	AA813641	Human myeloid deri
28	39	60.0	429	22	ABG19048	Novel human diapo
29	39	60.0	429	22	ABG74841	Human colon cancer
30	39	60.0	496	15	AA845938	A glycosyltransfer
31	39	60.0	802	22	ABG19045	Novel human diapo
32	39	60.0	880	22	ABG46332	Peptide P. abysal
33	39	60.0	7645	22	ABG29077	Novel human diapo
34	38	58.5	631	21	AA82816	JEST, a human SWAP
35	38	58.5	645	22	AA817060	novel signal trans
36	38	58.5	786	22	AA879287	Human protein SEQ
37	38	58.5	795	21	AA879287	Kat Ras signalling
38	38	58.5	1387	21	AA895441	Caenorhabditis ele
39	37	56.9	21	23	AA89857	Insulin/insulin-li
40	37	56.9	200	22	AA866650	Human bone marrow
41	37	56.9	209	23	ABG36384	Human peptide enco
42	37	56.9	219	22	ABG88980	Drosophila melano
43	37	56.9	246	22	ABG46332	Peptide P. abysal
44	37	56.9	299	22	AA814636	Novel bone marrow
45	47	56.9	406	14	AA852940	Pseudomonas sp. 12

ALIGNMENTS

RESULT 1			
AA82037			
1P	AA82037	standard, peptide: 13 AA.	
XX	AA82037		
AC	AA82037		
XX	14-JUN-2001	(first entry)	
XX	Human hepreceptor domain A binding peptide	Repe2032.	
DE	Human hepreceptor, cytosolic, anti-HIV; antiblotic		
XX	Human hepreceptor, cytosolic, anti-HIV; antiblotic		
KW	Human hepreceptor, cytosolic, anti-HIV; antiblotic		
KW	Human hepreceptor, cytosolic, anti-HIV; antiblotic		
OS	Homo sapiens.		
XX	Homo sapiens.		
XX	Key	location/Qualifiers	
PT	Modified-site	11	
FT		/note	"Optionally phosphorylated"
XX	GB2354241-A.		
PN	GB2354241-A.		
XX	21-MAR-2001.		
XX	17 SEP-1999.	9906-0021881.	
XX	17-SEP-1999.	9906-0021881.	
XX	(HOLM/)	HOLMS R D.	
XX	Holms RD;		
XX	WFI, 2001-29387/31.		

XX Novel regulatory or unfolding peptides of ezrin that binds to
PT heprecceptor, useful for inducing immune response for treating
PT infectious diseases and cancer -
XX
PS Claim 22; Page 46; 42pp; English.
XX The heprecceptor is a novel active site in human ezrin. Ezrin regulates
CC the structure of the cortical cytoskeleton to control cell surface
CC topography. The present invention relates to peptides (see AAB82021 to
CC AAB82041) that bind to heprecceptor with greater affinity than HEP1 (see
CC AAB82046). The heprecceptor binding peptides are useful for inducing
CC immune response, and for treating infectious diseases, cancer and
CC HIV-related dementia. The present peptide binds to domain A of the
CC heprecceptor (AAB82019).
XX
SQ Sequence 13 AA;
Query Match 100.0%; Score 65; PR 22; Length 13;
Best Local Similarity 100.0%; Pred. NO. 0.00055;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KEELMLRLQDYEE 13
DB 1 KEELMLRLQDYEE 13
RESULT 2
AAB82020
ID AAB82020 standard; peptide; 34 AA.
AC AAB82020;
XX
XX 13-JUN 2001 (first entry)
XX Human heprecceptor domain H.
XX Human; heprecceptor domain H; cytostatic; anti-HIV; antibiotic;
XX neurotropic; immune response inducer; ezrin; infectious diseases; cancer;
XX HIV-related dementia.
XX Homo sapiens.
XX
XX KEY location/qualifiers
XX Modified-site 14
XX /note- "optionally phosphorylated"
XX GB2454241-A.
XX 21-MAR 2001.
XX 17-SEP-1999; 99GB-0021881.
XX 17-SEP-1999; 99GB-0021881.
XX (HOLM/) HOLMS R D.
XX Holms RD;
XX
XX WPI: 2001 291287/31
XX Novel regulatory or unfolding peptides of ezrin that binds to
XX heprecceptor, useful for inducing immune response for treating
XX infectious diseases and cancer -
XX
XX Claim 5; Page 46; 42pp; English.
XX The present sequence is domain H of human heprecceptor of human ezrin. The
XX heprecceptor is a novel active site in human ezrin. Ezrin regulates the
XX structure of the cortical cytoskeleton to control cell surface
XX topography. The present invention relates to peptides (see AAB82021 to
XX AAB82041) that bind to heprecceptor with greater affinity than HEP1 (see
XX AAB82046). The heprecceptor binding peptides are useful for inducing

CC immune response, and for treating infectious diseases, cancer and
CC HIV related dementia. The present sequence assembles into two
CC anti-parallel helices with heprecceptor domain A (see AAB82019).
XX
SQ Sequence 34 AA;
Query Match 100.0%; Score 65; PR 22; Length 34;
Best Local Similarity 100.0%; Pred. NO. 0.0015;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KEELMLRLQDYEE 13
DB 4 KEELMLRLQDYEE 16
RESULT 3
AAG73954
ID AAG73954 standard; Protein; 436 AA.
XX
AC AAG73954;
XX
XX 03-SEP-2001 (first entry)
XX Human colon cancer antigen protein SEQ ID NO:4718.
XX Human; colon cancer; colon cancer antigen; diagnosis; detection;
XX colorectal carcinoma.
XX Homo sapiens.
XX
XX W0200122920-A2.
XX
XX 05-APR-2001.
XX 28-SEP-2009; 2009W0-0826524.
XX 29-SEP-1999; 99US-0157137.
XX 03-NOV-1999; 99US-0163280.
XX (HOMA-) HUMAN GENOME SCI INC.
XX Ruben SM, Harash SC, Hirse CE, Rosen CA;
XX WPI: 2001 235357/24.
XX N-PSDB; AAB33385.
XX Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
XX useful for preventing, diagnosing and/or treating colorectal cancers -
XX Claim 11; Page 6526 6521; 9803pp; English.
XX AAB32043 to AAB37105 and AAG73514 to AAG77788 represent human colon
XX cancer-associated nucleic acid molecules (N) and proteins (P), where
XX the proteins are collectively known as colon cancer antigens. The colon
XX cancer antigens have cytostatic activity and can be used in gene
XX therapy and vaccine production. N and P may be used in the prevention,
XX diagnosis and treatment of diseases associated with inappropriate P
XX expression. For example, N and P may be used to treat disorders
XX associated with decreased expression by rectifying mutations or deletions
XX in a patient's genome that affect the activity of P by expressing
XX inactive proteins or to supplement the patients own production of P.
XX Additionally, N may be used to produce the colon cancer-associated P,
XX by inserting the nucleic acids into a host cell and culturing the cell
XX to express the proteins. N and P can be used in the prevention, diagnosis
XX and treatment of colorectal carcinomas and cancers. AAB37196 to AAB7204
XX and AAB77789 represent sequences used in the exemplification of the
XX present invention.
XX N.R. Pages 666 to 682 and page 705 of the sequence listing were
XX missing at time of publication, meaning no sequences are present for
XX SEQ ID NO:1057 to 1052, 7921 and 7922.
XX
XX Sequence 436 AA;

Query Match 100.0%; Score 65; DB 22; Length 436;
 Best Local Similarity 100.0%; Pred. No. 0.02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13
 |||||

DB 194 KEELMLRLQDYEE 206

RESULT 4

AAV27443
 ID AAY27443 standard; protein; 586 AA.

XX AC AAY27443;

XX 26-NOV-1999 (first entry)

DT Amino acid sequence of human ezrin polypeptide.

DE Pharmaceutical; ezrin; mutant; tumor; metastasis, human.

XX Homo sapiens.

XX Key Location/Qualifiers

PH Misc-difference 354

FT /note= "the Tyr at this position can be mutated
 (preferably to a Phe) to construct an
 ezrin mutant of the invention"

FT W09947150-A2.

XX 23-SEP-1999.

XX 18-MAR-1999; 99WO-EP02054.

XX 18-MAR-1998; 98US-0040725.

XX (CURL-) INST CURIP

PA (CNRS) CNRS CENT NAT RECH SCI.

PI Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX WPI; 1999-561851/47.

XX New composition for prevention and treatment of tumors and metastasis

PT Example 1; Fig 1; 31pp; English.

PS The invention provides a pharmaceutical composition containing ezrin

XX protein, RNA or DNA mutated on tyrosine 353, or a functional fragment

CC derivative of the ezrin mutant. The new composition is useful for

CC prevention and/or treatment of tumors, and especially metastasis. The

CC present sequence represents the amino acid sequence of human ezrin

CC (before the maturation by deletion of the first amino acid Met).

XX Sequence 586 AA;

Query Match 100.0%; Score 65; DB 20; Length 586;
 Best Local Similarity 100.0%; Pred. No. 0.027;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13

DB 344 KEELMLRLQDYEE 356

RESULT 5

AAU30004
 ID AAU30004 standard; Protein; 622 AA.

XX AC AAU30004;

XX

DB 18-DEC-2001 (first entry)

XX Novel human secreted protein #495.

XX Human; vaccination, gene therapy, nutritional supplement;
 stem cell proliferation, hematopoiesis, nerve tissue regeneration;
 immune suppression, immune stimulation, anti-inflammatory, leukaemia.

XX Homo sapiens.

XX W0200179449-A2.

XX 25-OCT-2001.

XX 16-APR-2001; 2001WO-0508656.

XX 18-APR-2000; 2000US-0557929.

XX 26 JAN 2001; 2001US-0770160.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Drmanac RT;

XX WPI; 2001-611725/70.

XX Nucleic acids encoding a range of human polypeptides, useful in genetic
 vaccination, testing and therapy -
 Claim 20; Page 219; 765pp; English.

The invention relates to novel human secreted polypeptides. The
 polypeptides and antibodies to the polypeptides are useful for
 determining the presence of or predisposition to a disease associated
 with altered levels of polypeptide. The polypeptides are also useful for
 identifying agents (agonists and antagonists) that bind to them. Cells
 expressing the proteins are useful for identifying a therapeutic agent
 for use in treatment of a pathology related to aberrant expression or
 physiological interactions of the polypeptide. Vectors comprising
 the nucleic acids encoding the polypeptides and cells genetically
 engineered to express them are also useful for producing the proteins.
 The proteins are useful in genetic vaccination, testing and
 therapy, and can be used as nutritional supplements. They may be used to
 increase stem cell proliferation; to regulate haematopoiesis; and in
 bone, cartilage, tendon and/or nerve tissue growth or regeneration;
 immune suppression and/or stimulation; as anti-inflammatory agents; and
 in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
 sequences of novel human secreted proteins of the invention.

XX Sequence 622 AA;

Query Match 100.0%; Score 65; DB 22; Length 622;
 Best Local Similarity 100.0%; Pred. No. 0.029;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13

DB 380 KEELMLRLQDYEE 392

RESULT 6

AAH53356

ID AAH53356 standard; Protein; 635 AA.

XX AC AAH53356;

XX 09-MAR-2001 (first entry)

XX Human colon cancer antigen protein sequence Sbj ID No:896.

XX Human, colon cancer, colon cancer antigen; diagnosis; detection;
 identification; cytostatic; cardioactive; neuroprotective; vulnary;
 immunomodulatory; muscular; gynaecological; gastrointestinal;
 nephrotropic; antiinfective; antibacterial; gene therapy, wound;

KW neutral disorder; immune system disorder; muscular disorder;
 KW reproductive disorder; gastrointestinal disorder; renal disorder;
 KW infectious disease; cardiovascular disorder.
 XX
 OS Homo sapiens.
 XX
 PN W020005535-A1.
 XX
 PD 21-SEP-2000.
 XX
 PF 08 MAR-2000; 2000W0-0505883.
 XX
 PR 12 MAR-1999; 9903-0124279.
 XX
 PA (HUMAN) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Ruben SM;
 XX
 DR WPI: 2000-587534/55.
 DR N-PSDB; AAC58114.
 XX
 PT Colon cancer associated gene sequences, referred to as colon cancer
 PT antigens, useful for the treatment, prevention, and diagnosis of colon
 PT disorders such as colon cancer.
 XX
 PS Claim 11: Page 1449-1451; 2104pp; English.
 XX
 CC AAC97991 to AAC98763 encode the human colon cancer associated proteins,
 CC called human colon cancer antigens, given in AAC95324 to AAC94006. The
 CC human colon cancer antigens can have cytostatic, cardiocactive, muscular;
 CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
 CC uinary, nephrotropic, antineoplastic and antibacterial activities, and
 CC can be used in gene therapy. The colon cancer antigen polynucleotides,
 CC proteins and antibodies to the proteins are useful for the prevention,
 CC treatment and diagnosis of colon disorders, such as colon cancer. The
 CC polynucleotides may be used in diagnostics and research, such as for
 CC chromosome identification, and as hybridisation probes. The proteins
 CC may also be used to prevent diseases such as neural disorders, immune
 CC system disorders, muscular disorders, reproductive disorders,
 CC gastrointestinal disorders, wounds, renal disorders, infectious
 CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
 CC AAC94007 represent sequences used in the exemplification of the present
 CC invention.
 XX
 SQ Sequence 635 AA:
 Query Match 100.0%; Score 65; DB 21; Length 635;
 Best Local Similarity 100.0%; Pred. No. 0.03;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 KEELMLRLQDYEE 13
 Db 03 KEELMLRLQDYEE 405
 RESULT 7
 AA082038
 ID AA082038 standard; peptide; 12 AA.
 AC AA082038;
 XX
 DI 13-JUN 2001 (first entry)
 XX
 DE Human hepreceptor domain A binding peptide Rupe2132.
 XX
 KW Human; hepreceptor; cytostatic; anti-HIV; antibiotic;
 KW neotropic; immune response inducer; ezrin; infectious diseases; cancer;
 KW HIV-related dementia.
 XX
 OS Homo sapiens.
 XX
 PI Tang YT, Liu C, Drmanac RT;
 PR WPI: 2001-611725/70.
 XX

/note- "Optionally phosphorylated"
 FN GB2354241-A.
 XX
 PD 21-MAR-2001.
 XX
 PF 17-SEP-1999; 99GH-0021881.
 XX
 PR 17-SEP-1999; 99GB-0021881.
 XX
 PA (HOLM/) HOLMS R D.
 XX
 PI Holms RD;
 XX
 DR WPI: 2001-293287/31.
 XX
 PT Novel regulatory or unfolding peptides of ezrin that binds to
 PT hepreceptor, useful for inducing immune response for treating
 PT infectious diseases and cancer.
 XX
 PS Claim 24; Page 36; 42pp; English.
 XX
 CC The hepreceptor is a novel active site in human ezrin. Ezrin regulates
 CC the structure of the cortical cytoskeleton to control cell surface
 CC topography. The present invention relates to peptides (see AAB82021 to
 CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
 CC AAB82046). The hepreceptor binding peptides are useful for inducing
 CC immune response, and for treating infectious diseases, cancer and
 CC HIV-related dementia. The present peptide binds to domain A of the
 CC hepreceptor (AAB82019).
 XX
 SQ Sequence 12 AA:
 Query Match 92.3%; Score 60; DB 22; Length 12;
 Best Local Similarity 100.0%; Pred. No. 0.032;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2 EELMLRLQDYEE 13
 Db 1 EELMLRLQDYEE 12
 RESULT 8
 AA033060
 ID AA033060 standard; Protein; 52 AA.
 XX
 AC AA033060;
 XX
 DI 18-DEC-2001 (first entry)
 XX
 DE Novel human secreted protein #3551.
 XX
 KW Human; vaccination; gene therapy; nutritional supplement;
 KW stem cell; proliferation; haematopoiesis; nerve tissue regeneration;
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
 XX
 OS Homo sapiens.
 XX
 PN W020017449-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 16-APR-2001; 2001W0-0508656.
 XX
 PR 18-APR-2000; 2000US-0552929.
 XX
 PA 26-JAN-2001; 2001US-0770160.
 XX
 PI (HYPSE-) HYPSE INC.
 XX
 PI Tang YT, Liu C, Drmanac RT;
 PR WPI: 2001-611725/70.
 XX

PT Nucleic acids encoding a range of human polypeptides, useful in genetic
 PT vaccination, testing and therapy -
 PS Claim 20; Page 702; 765pp; English
 XX The invention relates to novel human secreted polypeptides. The
 CC polypeptides and antibodies to the polypeptides are useful for
 CC determining the presence of or predisposition to a disease associated
 CC with altered levels of polypeptide. The polypeptides are also useful for
 CC identifying agents (agonists and antagonists) that bind to them. Cells
 CC expressing the proteins are useful for identifying a therapeutic agent
 CC for use in treatment of a pathology related to aberrant expression or
 CC physiological interactions of the polypeptide. Vectors comprising
 CC the nucleic acids encoding the polypeptides and cells genetically
 CC engineered to express them are also useful for producing the proteins.
 CC The proteins are useful in genetic vaccination, testing and
 CC therapy, and can be used as nutritional supplements. They may be used to
 CC increase stem cell proliferation; to regulate haematopoiesis; and in
 CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
 CC immune suppression and/or stimulation; as anti-inflammatory agents; and
 CC in treatment of leukaemias. AA029510-AA03304 represent the amino acid
 CC sequences of novel human secreted proteins of the invention.
 XX
 SQ Sequence 52 AA;

Query Match 87.7%; Score 57; DP 22; Length 52;
 Best Local Similarity 92.3%; Pred. No. 0.043;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13
 Db 12 KEELMLRLQDYEE 24

RESULT 9
 AAB82039
 ID AAB82039 standard; peptide; 11 AA.

XX AAB82039;

XX 13-JUN-2001 (first entry)

XX Human heptareceptor domain A binding peptide Eupr2232.

XX Human, heptareceptor, cytosolic, anti-HIV; antibiotic;
 KW neotropic, immune response inducer, ezrin, infectious diseases, cancer;
 KW HIV-related dementia.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Modified-site 9 /note- "Optionally phosphorylated"

FT FT

PN GB2354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99CH-0021881.

XX 17-SEP-1999; 99GB-0021881.

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001 293287/31.

XX Novel regulatory or binding peptides of ezrin that binds to
 PT heptareceptor, useful for inducing immune response for treating
 PT infectious diseases and cancer -

XX Claim 26; Page 37; 42pp; English.

XX The heptareceptor is a novel active site in human ezrin. Ezrin regulates
 CC the structure of the cortical cytoskeleton to control cell surface
 CC topography; the present invention relates to peptides (see AAB82039 to
 CC AAB82041) that bind to heptareceptor with greater affinity than HBP1 (see
 CC AAB82046). The heptareceptor binding peptides are useful for inducing
 CC immune response, and for treating infectious diseases, cancer and
 CC HIV-related dementia. The present peptide binds to domain A of the
 CC heptareceptor (AAB82019).

SQ Sequence 11 AA;

Query Match 84.6%; Score 55; DP 22; Length 11;
 Best Local Similarity 100.0%; Pred. No. 0.018;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 ELMRLQDYEE 13
 Db 1 ELMRLQDYEE 11

RESULT 10

AAV27444

ID AAV27444 standard; peptide; 27 AA.

XX AAV27444;

XX 26-NOV-1999 (first entry)

XX Antennapedia internalization sequence in tandem with ezrin fragment.
 DE Pharmacological, ezrin, mutant, tumor, antennapedia internalization;
 KW metastasis; human.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 1 /note- "biotinylated"

FT Modified-site 22

FT /note "optionally phosphorylated"

XX W09947150 A2.

XX 23-SEP-1999.

XX 18-MAR-1999; 99WO-EP02054.

XX 18-MAR-1998; 98US-0040725.

XX (CURT-) INST CURTE.

XX (CNRS) CNRS CENT NAT RECH SCI.

XX Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX WPI: 1999-561851/47.

XX New composition for prevention and treatment of tumors and metastasis
 FT
 PI
 XX
 PS Example 5; Page 14; 31pp; English.

XX The invention provides a pharmacological composition containing ezrin
 CC protein, RNA or DNA mutated on tyrosine 353, or a functional fragment
 CC or derivative of the ezrin mutant. The new composition is useful for
 CC prevention and/or treatment of tumors, and especially metastasis. The
 CC present sequence represents an antennapedia internalization sequence in
 CC tandem with an ezrin fragment (residues 348-358). This is used in
 CC experiments of p85 interaction with phosphorylated ezrin peptides.

SQ Sequence 27 AA;

Query Match 62.1%; Score 41; DP 20; Length 27;

Best Local Similarity 100.0%; Pred. No. 7.7;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 LKMLQDYEE 13
DB 17 LKMLQDYEE 24

RESULT 11
AB029165
ID AB029165 standard; Protein: 444 AA.

XX AC AB029165;

XX DT 13-FEB-2002 (first entry)

XX DE Novel human diagnostic protein #29156.

XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN W0200175067-A2.

XX PD 11-OCT 2001.

XX PF 30-MAR-2001; 2001WO-US08641

XX PR 31-MAR-2001; 2001US-054017

XX PR 24-AUG-2001; 2001US-0649167

XX PA (HVSF) HYSEQ INC.

XX PI Ormanac Rd, Lin C, Tang YL;

XX WPI: 2001-69362/73.

XX N-PSDB: AAS93352.

XX PI New isolated polynucleotide and encoded polypeptides, useful in
PI diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity.

XX PS Claim 20; SEQ ID No 59524; 103pp; English.

XX CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (I) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detection or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AB00010-AB03077 represent novel human
CC diagnostic amino acid sequences of the invention.

XX Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 344 AA;

Query Match: 63.1%; Score 41; DB 22; Length 344;

Best Local Similarity 72.7%; Pred. No. 1e+02;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 KEELMLQDYEE 12
DB 278 KEELMLQDYEE 288

RESULT 12
AB042735
ID AB042735 standard; Peptide: 46 AA.

XX AC AB042735;

XX DT 04-FEB-2002 (first entry)

XX DE Peptide #10241 encoded by human foetal liver single exon probe.

XX KW Human, foetal liver; gene expression; single exon nucleic acid probe.

XX OS Homo sapiens.

XX PN W0200157277-A2.

XX PD 09-AUG-2001.

XX PF 30-JAN-2001; 2001WO-US00669.

XX PR 04-FEB-2001; 2000US-0180312.

XX PR 26-MAY-2001; 2000US-0207456.

XX PR 30-JUN-2001; 2000US-0608408.

XX PR 03-AUG-2001; 2000US-0632366.

XX PR 21-SEP-2001; 2000US-0214687.

XX PR 27-SEP-2001; 2000US-0216359.

XX PR 04-OCT-2001; 2000US-0224263.

XX PA (MOLE-) MOLECULAR DYNAMICS INC.

XX PI Fern SG, Hanzel DK, Chen W, Rank DR;

XX WPI: 2001-483447/52.

XX PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human foetal liver.

XX PS Claim 27; SEQ ID No 35370; 639pp + sequence listing; English.

XX CC The invention relates to a single exon nucleic acid probe for
CC measuring human gene expression in a sample derived from human foetal
CC liver. The single exon nucleic acid probes may be used for prediction,
CC measuring and displaying gene expression in samples derived from human
CC foetal liver. The present sequence is a peptide encoded by a single exon
CC nucleic acid probe of the invention.

XX Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 46 AA;

Query Match: 61.5%; Score 40; DB 22; Length 46;

Best Local Similarity 53.8%; Pred. No. 19;

Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 KEELMLQDYEE 13
DB 31 K0NLLLELRNYEE 43

RESULT 13
AAM63626
ID AAM63626 standard; Protein: 46 AA.

XX AC AAM63626;

XX DT 05-NOV-2001 (first entry)

XX DE Human brain expressed single exon probe encoded protein SEQ ID NO: 35731
 XX KW Human; brain expressed exon; gene expression analysis; probe;
 KW microarray; Alzheimer's disease, multiple sclerosis, schizophrenia,
 KW epilepsy; cancer.
 XX OS Homo sapiens.
 XX PN W0200157275-A2.
 XX PD 09-AUG-2001.
 XX PF 30-JAN-2001; 2001WO 030967.
 XX PP 04-FEB-2000; 2000US 0189312.
 XX PP 26-MAY-2000; 2000US 0297156.
 XX PR 30-JUN-2000; 2000US 0608408.
 XX PR 03-AUG-2000; 2000US 0432365.
 XX PR 21-SEP-2000; 2000US 0244695.
 XX PP 27-SEP-2000; 2000US 0246359.
 XX PP 04-OCT-2000; 2000US 0244263.
 XX PA (MOLFE-) MOLECULAR DYNAMICS INC.
 XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
 XX WPI: 2001-483446/52.
 XX Single exon nucleic acid probes for analyzing gene expression in human
 XX brains.
 XX Example 4: SEQ ID NO: 35731; 650pp + Sequence Listing; English
 XX The present invention provides a number of single exon nucleic acid
 XX probes which are derived from genomic sequences expressed in the human
 XX brain. They can be used to measure gene expression in brain cell samples,
 XX which may enable the diagnosis and improved treatment of nervous system
 XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
 XX epilepsy and cancers. The present sequence is a protein encoded by one of
 XX the probes of the invention.
 XX SQ Sequence 46 AA;
 Query Match 61.5%; Score 40; DB 22; Length 46;
 Best Local Similarity 54.8%; Pred. No. 19;
 Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1 KEELMLRLODYEE 13
 I: I: I: I: I: I:
 Db 31 KQNLLELNYYE 43

RESULT 14
 ABG16577
 ID ABG16577 standard; Protein; 503 AA.
 XX AC ABG16577;
 XX DT 18-FEB-2002 (first entry)
 XX DE Novel human diagnostic protein #16568.
 XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX OS Homo sapiens.
 XX PN W0200175067-A2.
 XX PD 11-OCT-2001.
 XX PF 30-MAR-2001; 2001WO-US08631

XX X1-MAP-2000; 2000US-0540217.
 XX 23-AUG-2000; 2000US-0649167.
 XX (HISE) HISEQ INC.
 XX Drmanac RI, Liu C, Tang YT;
 XX WPI: 2001-639462/73.
 XX N-PSDB; AAS80764.
 XX New isolated polynucleotide and encoded polypeptides, useful in
 XX diagnostics, forensics, gene mapping, identification of mutations
 XX responsible for genetic disorders or other traits and to assess
 XX biodiversity.
 XX Claim 20, SEQ ID NO 45336, 103pp; English.
 XX The invention relates to isolated polynucleotide (I) and
 XX polypeptide (II) sequences. (I) is useful as hybridisation probes,
 XX polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 XX and gene mapping, and in recombinant production of (II). The
 XX polynucleotides are also used in diagnostics as expressed sequence tags
 XX for identifying expressed genes. (I) is useful in gene therapy techniques
 XX to restore normal activity of (II) or to treat disease states involving
 XX (II). (II) is useful for generating antibodies against it, detecting or
 XX quantitating a polypeptide in tissue, as molecular weight markers and as
 XX a food supplement. (II) and its binding partners are useful in medical
 XX imaging of sites expressing (II). (I) and (II) are useful for treating
 XX disorders involving aberrant protein expression or biological activity.
 XX The polypeptide and polynucleotide sequences have applications in
 XX diagnostics, forensics, gene mapping, identification of mutations
 XX responsible for genetic disorders or other traits to assess biodiversity
 XX and to produce other types of data and products dependent on DNA and
 XX amino acid sequences. AAG06010-AAG30377 represent novel human
 XX diagnostic amino acid sequences of the invention.
 XX Note: the sequence data for this patent did not appear in the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pat_sequences.
 XX SQ Sequence 503 AA;
 Query Match 61.5%; Score 40; DB 22; Length 503;
 Best Local Similarity 59.2%; Pred. No. 23002;
 Matches 9; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
 QY 1 KEELMLRLODYEE 13
 I: I: I: I: I: I:
 Db 264 KEELMLRLODYEE 276
 RESULT 15
 ABG19947
 ID ABG19947 standard; Protein; 593 AA.
 XX AC ABG19947;
 XX DT 18-FEB-2002 (first entry)
 XX DE Novel human diagnostic protein #19938.
 XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX OS Homo sapiens.
 XX PN W0200175067-A2.
 XX PD 11-OCT-2001.
 XX PF 30-MAR-2001; 2001WO-US08631.
 XX PF 31-MAR-2000; 2000US-0540217.

Pr 23 AUG-2000; 2000US 0649167.
 XX (HYSEQ) HYSEQ INC.
 XX Drmanac RT, Liu C, Tang YF;
 XX WPI: 2001-639462/73.
 DR N-ESDB; AAS84144.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity.
 XX
 PS Claim 20; SEQ ID NO 50406; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. AAG00010-AAG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at http://wipo.int/pub/published_pat_sequences.

XX Sequence 593 AA;

Query Match 61.5%; Score 40; DH 22; Length 593;

Best Local Similarity 69.2%; Pred. No. 2.6e+02;

Matches 9; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 KEELMERKQYEE 13

|||||||

Db 359 KEELMERKQYEE 371

Search completed: January 16, 2003, 16:49:14

Job time : 62.8429 secs